TIPARP and neoplasm: A series of potent radiolabeled antagonists, 111In- and 68Ga- labeled RM1 (where RM1 = DO3A-CH2CO-G-[4-aminobenzyl]- D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2, where Sta is a statyl residue Figure 1) and 111In-labeled RM2 peptides, showed higher tumor uptake and better pharmacokinetics than the corresponding agonists [32,33].